News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Zenyth And MuriGen Collaborate On Inflammation Targets
February 20, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Zenyth Therapeutics (ASX:ZTL), formerly Amrad, and unlisted Walter and Eliza Hall Institute (WEHI) spinout MuriGen Therapeutics are to co-develop a new class of drugs that target arthritis and other inflammatory diseases. More...
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Australia
MORE ON THIS TOPIC
Deals
Astellas Divorces CytomX Despite Positive Phase 1 Data for Antibody Platform
March 17, 2026
·
2 min read
·
Tristan Manalac
Layoff Tracker
Inovio Slims Down as Lead Asset Nears Market
March 16, 2026
·
36 min read
·
BioSpace Editorial Staff
Earnings
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
March 13, 2026
·
5 min read
·
Annalee Armstrong
Rare diseases
Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate
March 13, 2026
·
2 min read
·
Tristan Manalac
